These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34420983)

  • 41. Paraneoplastic pityriasis rubra pilaris as the presenting manifestation of metastatic squamous cell carcinoma.
    Remedios IM; Jensen JD; Beckum K; McKay K; Kissel R
    J Drugs Dermatol; 2014 May; 13(5):610-2. PubMed ID: 24809888
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
    Bramhoff AC; Wesselmann U; Bender ST; Berghoff AV; Hofmann SC; Balakirski G
    Dermatologie (Heidelb); 2022 Aug; 73(8):634-637. PubMed ID: 35296923
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pityriasis rubra pilaris. A clinico-pathological study with a special reference to autoradiography and histocompatibility antigens.
    Niemi KM; Kousa M; Storgards K; Karvonen J
    Dermatologica; 1976; 152(2):109-18. PubMed ID: 939336
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An unusual cluster of circumscribed juvenile pityriasis rubra pilaris cases.
    Martin KL; Holland KE; Lyon V; Chiu YE
    Pediatr Dermatol; 2014; 31(2):138-45. PubMed ID: 24456130
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Changing forms of juvenile pityriasis rubra pilaris--a case report.
    Shahidullah H; Aldridge RD
    Clin Exp Dermatol; 1994 May; 19(3):254-6. PubMed ID: 8033391
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
    Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
    Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Early presentation of pityriasis rubra pilaris.
    Caplan SE; Lowitt MH; Kao GF
    Cutis; 1997 Dec; 60(6):291-6. PubMed ID: 9426969
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A case of pityriasis rubra pilaris following AstraZeneca COVID-19 vaccine.
    Wada M; Lee S; Curnow P; Simpson I; Mar A
    JAAD Case Rep; 2022 Jun; 24():74-77. PubMed ID: 35529074
    [No Abstract]   [Full Text] [Related]  

  • 49. Adalimumab for the treatment of pityriasis rubra pilaris: a case report.
    Wassef C; Lombardi A; Rao BK
    Cutis; 2012 Nov; 90(5):244-7. PubMed ID: 23270195
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Secukinumab monotherapy successfully treated severe refractory type V (atypical juvenile) pityriasis rubra pilaris: A case report and literature review.
    Liang JY; Ye RX; Tian X; Zhang SQ; Zhang XB
    Dermatol Ther; 2020 Nov; 33(6):e14097. PubMed ID: 32725719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pityriasis rubra pilaris after Vaxzevria® COVID-19 vaccine.
    Lladó I; Butrón B; Sampedro-Ruiz R; Fraga J; de Argila D
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):e833-e835. PubMed ID: 34310778
    [No Abstract]   [Full Text] [Related]  

  • 52. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
    Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
    Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Arthritis associated with pityriasis rubra pilaris.
    Liu PY; Prete PE
    BMJ Case Rep; 2010 Aug; 2010():. PubMed ID: 22766575
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pityriasis rubra pilaris-like eruption following insulin therapy initiation.
    Badri T; Zaouak A; Lakhoua G; Koubaa W; Fennich S; Zaiem A
    Dermatol Pract Concept; 2016 Oct; 6(4):19-21. PubMed ID: 27867741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erythrodermic pityriasis rubra pilaris after SARS-CoV-2 vaccination with concomitant COVID-19 infection.
    Gambichler T; Scheel CH; Arafat Y; Kautz O; Boms S
    J Eur Acad Dermatol Venereol; 2022 Sep; 36(9):e675-e676. PubMed ID: 35536694
    [No Abstract]   [Full Text] [Related]  

  • 56. Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris: A Case Series of 100 Patients.
    Ross NA; Chung HJ; Li Q; Andrews JP; Keller MS; Uitto J
    JAMA Dermatol; 2016 Jun; 152(6):670-5. PubMed ID: 26963004
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature.
    Nguyen CV; Farah RS; Maguiness SM; Miller DD
    Pediatr Dermatol; 2017 Jan; 34(1):e65-e68. PubMed ID: 27874201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histopathologic findings characteristic of CARD14-associated papulosquamous eruption.
    Ring NG; Craiglow BG; Panse G; Antaya RJ; Ashack K; Ashack R; Faith EF; Paller AS; McNiff JM; Choate KA; Ko CJ
    J Cutan Pathol; 2020 May; 47(5):425-430. PubMed ID: 31849081
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pityriasis rubra pilaris following inactivated SARS-CoV-2 vaccine (CoronaVac).
    Zhang LW; Wang WJ; Fu LX; Lu YH; Chen T; Xu RH
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):e287-e288. PubMed ID: 36504416
    [No Abstract]   [Full Text] [Related]  

  • 60. Pityriasis rubra pilaris as a systemic disease.
    Kamarachev J; Grozdev I; Darlenski R; Tsankov N
    Clin Dermatol; 2019; 37(6):657-662. PubMed ID: 31864444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.